Related Experiment Video
Updated: Jul 15, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Scaffold targeting drug-resistant colon cancers
Katerina Otrubova1, Kathleen L McGuire, Shelli R McAlpine
1Department of Chemistry and Biochemistry, 5500 Campanile Road, San Diego State University, San Diego, California 92182-1030, USA.
Abstract:
We have identified five derivatives of the natural product sansalvamide A that are potent against multiple drug-resistant colon cancer cell lines. These analogs share no structural homology to current colon cancer drugs, are cytotoxic at levels on par with existing drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell lines over noncancerous cell lines. Thus, we have established sansalvamide A as a privileged structure for treating multiple drug-resistant colon cancers.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drugs that Destabilize Microtubules

